Alectinib, an inhibitor of anaplastic lymphoma kinase (ALK), was approved by the Food and Drug Administration (FDA) for the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC). Here we investigated the reversal effect of alectinib on multidrug resistance (MDR) induced by ATP-binding cassette (ABC) transporters, which is the primary cause of chemotherapy failure. We provide the first evidence that alectinib increases the sensitivity of ABCB1-and ABCG2-overexpressing cells to chemotherapeutic agents in vitro and in vivo. Mechanistically, alectinib increased the intracellular accumulation of ABCB1/ABCG2 substrates such as doxorubicin (DOX) and Rhodamine 123 (Rho 123) by inhibiting the efflux function of the transporters in ABCB1-or ABCG2-overexpressing cells but not in their parental sensitive cells. Furthermore, alectinib stimulated ATPase activity and competed with substrates of ABCB1 or ABCG2 and competed with [125I] iodoarylazidoprazosin (IAAP) photolabeling bound to ABCB1 or ABCG2 but neither altered the expression and localization of ABCB1 or ABCG2 nor the phosphorylation levels of AKT and ERK. Alectinib also enhanced the cytotoxicity of DOX and the intracellular accumulation of Rho 123 in ABCB1-overexpressing primary leukemia cells. These findings suggest that alectinib combined with traditional chemotherapy may be beneficial to patients with ABCB1-or ABCG2-mediated MDR.
INTRODUCTION
Chemotherapy is the mainstay of treatment for many human cancers. Unfortunately, the successful treatment of cancers with chemotherapeutic drugs is usually hindered by MDR. Cancer cells with multidrug resistance (MDR) become simultaneously resistant to a variety of structurally and functionally unrelated anticancer drugs. 1,2 Among the various factors contributing to the development of MDR, the overexpression of ABC transporters, particularly ATP-binding cassette subfamily B member 1 (ABCB1), ATP-binding cassette subfamily C member 1 (ABCC1) and ATP-binding cassette subfamily G member 2 (ABCG2), is considered to be a primary determinant of MDR. 3, 4 Functionally, ABC transporters can pump chemotherapeutic agent out of cancer cells and decrease the intracellular accumulation of chemotherapeutic agents, resulting in drug resistance in MDR cells.
ABCB1 (P-glycoprotein, P-gp), the first identified eukaryotic ABC transporter that conferred MDR in cancer cells, is composed of two homologous halves, each containing six transmembrane domains and an ATP binding/utilization domain, separated by a flexible polypeptide linker. 5 ABCB1 can transport a wide range of hydrophobic compounds, including vinca alkaloids (vinblastine and vincristine), anthracyclines (doxorubicin and daunorubicin), epipodophyllotoxins, taxanes and some tyrosine kinase inhibitors (TKIs), out of cells. Overexpression of ABCB1 is also associated with poor prognosis of cancer patients. [6] [7] [8] ABCG2 (breast cancer resistance protein (BCRP), mitoxantrone resistance protein, ATP-binding assette of placenta) is known as a half transporter that effluxes drugs with amphiphilic properties. 9,10 ABCG2 has been reported to mediate MDR to a wide variety of anticancer drugs, including mitoxantrone, topotecan, irinotecan, doxorubicin, nilotinib and imatinib. 9, [11] [12] [13] Over the past decades, numerous studies have been devoted to developing ABC transporter inhibitors. 14, 15 However, none of these inhibitors has been successful in clinical practice due to poor efficacy and unpredictable adverse effects in patients. 16 Fortunately, significant efforts have been made to devise new strategies to overcome MDR to cancer chemotherapy, and the addition of TKIs to combination regimens has gained traction. 17 It is known that TKIs can bind to the ATP-binding site of tyrosine kinase, and therefore, it is conceivable that TKIs may bind to the ATP-binding site of ABC transporters. Previous studies have reported that several TKIs, including lapatinib, erlotinib, apatinib and afatinib, were able to modulate the MDR phenotype mediated by ABC transporters and encouraged evaluations of the potential of these TKIs to circumvent the anticancer drug resistance in clinical trials. [18] [19] [20] [21] [22] [23] Alectinib, an orally active ATP-competitive anaplastic lymphoma kinase (ALK) inhibitor, was approved by the FDA for the treatment of the patients with ALK-positive NSCLC. 1, 21, [24] [25] [26] [27] In clinical trials, alectinib induced promising anti-tumor activity in NSCLC patients with altered ALK activity or crizotinib resistance. 28, 29 In this study, we investigated the effect of alectinib on the reversal MDR induced by ABCB1 or ABCG2 in vitro, in vivo and ex vivo.
MATERIALS AND METHODS

Chemicals and reagents
Alectinib was purchased from KareBay Biochem (Monmouth Junction, NJ, USA). The formula of Alectinib is presented in Figure 1a . Antibodies against ABCB1/p-gp (sc-13131), ABCG2 (sc-377176), AKT (sc-8312), p-AKT (sc-7985-R), ERK (sc-514302) and p-ERK (sc-7383) were from Santa Cruz Biotechnology Inc. (Paso Robles, CA, USA). Flow cytometry antibodies against ABCB1 (#557002) and mouse IgG2b/κ (#559532) were purchased from BD Biosciences (San Jose, CA, USA), and ABCG2 (sc-18841) was from Santa Cruz Biotechnology Inc. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was from Kangchen Co. (Shanghai, China). SYBR Green qPCR Master Mix was from ExCell Bio (Shanghai, China). Dulbecco's modified Eagle's medium and RPMI 1640 medium were purchased from Thermo Fisher Scientific Inc. (Waltham, MA, USA). Rhodamine 123 (Rho 123), 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT), G418, paclitaxel, doxorubicin (DOX), vincristine (VCR), verapamil (VRP), topotecan, mitoxantrone (MX), cisplatin, fumitremorgin C (FTC) and other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Cell lines and cell culture
The human oral epidermoid carcinoma cell line KB and its vincristine (VCR)-selected ABCB1-overexpressing cell line KBv200 were cultured in RPMI 1640 supplemented with 10% FBS at 37°C in the presence of 5% CO 2 . The NSCLC cell line H460 and its mitoxantrone (MX)-selected ABCG2-overexpressing cell line H460/MX20, human colon carcinoma cell line S1 and its MX-selected ABCG2-overexpressing cell line S1-MI-80 were generous gifts from Dr Susan Bates (NCI, NIH, Bethesda, MD, USA). The human breast carcinoma cell line MCF-7 and its DOX-selected ABCB1-overexpressing cell line MCF-7/adr; transfected HEK293/Vector, HEK293/ABCB1 and HEK293/ABCG2 (wild type) cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% FBS at 37°C in the presence of 5% CO 2 . The transfected cells were cultured in medium containing 2 mg ml − 1 G418. [30] [31] [32] [33] Cell cytotoxicity assay MTT assays were used to assess cell sensitivity to drugs as previously described. 34 The concentration required to inhibit cell growth by 50% (IC 50 ) was calculated from survival curves by the Bliss method. 35 The degree of reversal of MDR (fold reversal) was calculated by dividing the IC 50 for cells with the chemotherapeutic agent in the absence of alectinib by that obtained in the presence of alectinib.
Animal experiments
The KBv200 cell xenograft model was established as previously described. 36 All experiments were performed in accordance with the guidelines for the Use of Laboratory Animals of Sun Yat-sen University Cancer Center after agreement of the Animal Experimental Ethics Review Committee of Sun Yat-sen University Cancer Center. Briefly, KBv200 cells (2.0 × 10 6 ) were subcutaneously injected into the right flanks of athymic nude mice (BALB/c-nu/nu, 5-6 weeks of age, 18-24 g in weight). The mice were randomized into four groups and received the following various treatments: (a) saline (q3d); (b) paclitaxel (20 mg kg − 1 , intraperitoneal injection/i.p., q3d); (c) alectinib (12 mg kg − 1 , gavage, q3d); (d) alectinib (12 mg kg − 1 , gavage, q3d, given 1 h before paclitaxel administration) plus paclitaxel (20 mg kg − 1 , i.p., q3d). When the tumor size reached a mean diameter of 5 mm, the body weights of the animals and the two perpendicular tumor diameters (A and B) were measured every 2 days, and the tumor volume (V) was calculated according to the following formula:
. At the end of the observation period, the mice were killed, and the xenografts were excised and weighed. The tumor volume and animal body weight were plotted against the time of treatment. The ratio of tumor growth inhibition (IR) was estimated according to the following formula: 37 IRð%Þ ¼ ð1 À Mean tumor weight of experimental group= Mean tumor weight of control groupÞ 100%
DOX and Rho 123 accumulation assay
Flow cytometry assays were performed to measure the effect of alectinib on the cellular accumulation of DOX and Rho 123 in the cancer cells as previously described. 31 Briefly, the cells were incubated with different concentrations of alectinib or vehicle at 37°C for 3 h. Following alectinib treatment, 10 μM DOX or 5 μM Rho 123 was added, and incubation was continued for an additional 3 or 0.5 h, respectively. The cells were then harvested, washed three times with chilled phosphate-buffered saline (PBS), and analyzed by flow cytometry (Cytomics FC500, Beckman Coulter Inc., Brea, CA, USA). VRP and fumitremorgin C (FTC) were used as positive control inhibitors of ABCB1 and ABCG2, respectively.
Rho 123 efflux assay
Rho 123 efflux assays were performed as previously described. 38 Cells were treated with 5 μM Rho 123 at 37°C for 30 min. Then, the cells were washed three times with PBS and were then subsequently incubated at 37°C with fresh media in the presence or absence of 1.5 μM alectinib. The cells were collected at the desired times and immediately washed three times with chilled PBS. Finally, the cells were resuspended in chilled PBS and then immediately subjected to flow cytometric analysis (Cytomics FC500, Beckman Coulte Inc.).
ABCB1 and ABCG2 ATPase activity assays
A colorimetric ATPase assay was performed as previously described with minor modifications. 39 Briefly, crude membrane isolated from
High Five insect cells expressing either ABCB1 or ABCG2 (100 μg protein per ml) was incubated at 37°C with a range of different concentrations of alectinib in the presence or absence of sodium orvanadate (0.3 mM for ABCB1 and 1.2 mM for ABCG2) in ATPase assay buffer (50 mM KCl, 5 mM sodium azide, 2 mM EDTA, 10 mM MgCl 2 , 1 mM DTT, pH 6.8) for 5 min. ATP hydrolysis reaction was then initiated by the addition of 5 mM Mg-ATP (concentration in a final volume of 60 μl) and then incubated for 20 min (for ABCB1) or Figure 1 The structure and cytotoxicity of alectinib. The structure of alectinib (a). The expression levels of ABCG2 and ABCB1 were detected in KB cells, ABCB1-overexpressing KBv200 cells, S1 cells and ABCG2-overexpressing S1-MI-80 cells (b). MTT assays were used to assess the cell survival in KB cells and ABCB1-overexpressing KBv200 cells (c), MCF-7 and ABCB1-overexpressing MCF-7/adr cells (d), S1 and ABCG2-overexpressing S1-MI-80 cells (e), H460 and ABCG2-overexpressing H460/MX20 cells (f), HEK293/Vector and stable ABCB1 transfected HEK293/ABCB1 cells (g), and HEK293/Vector and stable ABCG2 transfected HEK293/ABCG2-R2 cells (h). All cells were treated with a full range of alectinib concentrations for 72 h. The data points represent the mean ± s.d. of at least three independent experiments performed in quadruple.
10 min (for ABCG2). SDS solution (30 μl of 10% SDS) was added to terminate the reaction. The absorbance was subsequently measured at 750 nm after the addition of a detection reagent (35 mM ammonium molybdate, 15 mM zinc acetate, 10% ascorbic acid) and incubation at 37°C for 20 min. The amount of inorganic phosphate released was quantified by reading from a standard curve. Specific alectinibstimulated ABCB1 and ABCG2 ATPase activity (that is, vanadatesensitive) was determined as the difference between the amounts of inorganic phosphate released from ATP in the absence and presence of sodium orvanadate.
Photo-affinity labeling of ABCB1 and ABCG2 with [ 125 I]-IAAP
Crude membrane from High Five insect cells expressing ABCB1 or ABCG2 (50 μg protein) was incubated with 0-10 μM alectinib for 5 min at room temperature in 50 mM Tris-HCl (pH 7.5).
[ 125 I]-IAAP (2200 Ci nmol − 1 , 3 nM) was added, and incubation was continued for another 5 min under subdued light. The samples were then crosslinked by UV illumination (365 nm) on ice. The labeled ABCB1 and ABCG2 were immunoprecipitated using the corresponding antibody. The samples were then subjected to SDS-polyacrylamide gel electrophoresis using a 7% Tris-acetate NuPAGE gel, dried and exposed to Bio-Max MR film (Eastman Kodak Co., Rochester, NY, USA) at − 80°C overnight. The radioactivity incorporated into the transporter protein was quantified using a Storm 860 Phosphor Imager system (Molecular Dynamics, Sunnyvale, CA, USA). 39 
Western blot analysis
Western blot analysis was performed as previously described. 22 The signal was detected using enhanced chemiluminescence solutions (#1705061, Bio-Rad, CA, USA) and exposed to a Kodak medical X-ray processor (Kodak, Rochester, NY, USA).
PCR and real-time quantitative PCR
ABCB1 and ABCG2 mRNA expression levels were assayed as previously described. 22 The PCR primers were 5′-CAGGCTTGCTGTA ATTACCCA-3′ (forward) and 5′-TCAAAGAAACAACGGTTCGG-3′ (reverse) for ABCB1; 5′-TGGCTGTCATGGCTTCAGTA-3′ (forward) and 5′-GCCACGTGATTCTTCCACAA-3′ (reverse) for ABCG2; 5′-GAGTCAAGGATTTGGTCGT-3′(forward) and 5′-GATCTCGCT CCTGGAAGATG-3′(reverse) for GAPDH. The relative expression of ABCB1 or ABCG2 was quantified using the 2 -ΔΔCt method after normalization with GAPDH expression in each sample. 40 Cell surface expression of ABCB1 and ABCG2 examined by flow cytometry
Cell surface expression of ABCB1 or ABCG2 in KBv200 or S1-MI-80 cells was measured by flow cytometry after treated with the desired concentrations of alectinib for 48 h. Flow cytometry analysis was performed as previously described. 40 
Patient samples
Bone marrow samples from diagnosed acute myeloid leukemia (AML) or chronic myelogenous leukemia (CML) patients according to the French-American-British (FAB) classification were obtained after patients provided informed consent. 41 This study was approved by the Ethics Review Committee of Sun Yat-sen University. Leukemic blasts were isolated using Ficoll-Hypaque density gradient by centrifugation and then cultured in RPMI 1640 medium.
Statistics
The results are shown as the mean ± s.d. All experiments were repeated at least three times, and differences were determined by using Student's t-test. Statistical significance was considered as *Po0.05, **Po0.01. Tables 1 and 2 ). These data suggest that ABCB1-and ABCG2-overexpressing MDR cells were extremely resistant to substrate conventional chemotherapeutic agents compared with their parental sensitive cells. Furthermore, co-treatment with alectinib led to significant decreases in the IC 50 values of established ABCB1 and ABCG2 substrates in high-level ABCB1-and ABCG2-expressing cells in, respectively, an alectinib concentration-dependent manner. However, the IC 50 values of established ABCB1 and ABCG2 substrates (such as VCR, DOX, paclitaxel and topotecan) in the absence of alectinib showed no significant difference in drug-sensitive cells (Supplementary Tables 1 and 2 ). In addition, alectinib did not alter the IC50 values of cisplatin, which is not a substrate of ABCB1 or ABCG2 in ABCB1-or ABCG2-overexpressing cells relative to their parental sensitive cells (Supplementary Tables 1  and 2 ). These results indicate that alectinib can strongly enhance the efficacy of conventional chemotherapeutic agents such as VCR, DOX, paclitaxel and topotecan in ABCB1-and ABCG2-mediated MDR cancer cells in vitro.
RESULTS
Alectinib
Alectinib potentiated the anticancer efficacy of paclitaxel in a model of ABCB1-overexpressing KBv200 cell xenografts in vivo To investigate whether alectinib could enhance the efficacy of anticancer drugs in vivo, we established a ABCB1-overexpressing multidrug-resistant KBv200 cell xenograft model in nude mice. Paclitaxel has been one of the most commonly used conventional chemotherapeutic agents for oral Reversal of MDR by alectinib K Yang et al cancers in the clinic. 42 Therefore, we performed KBv200 cell xenografts using paclitaxel. The xenograft growth inhibitions in the alectinib, paclitaxel or combined treatment groups were 1.36%, 11.32% or 48.33%, respectively. There was no significant difference in tumor size among animals treated with saline, alectinib or paclitaxel alone. However, the combination of alectinib and paclitaxel induced a significant greater inhibitory effect on xenograft growth compared with the animals treated with only saline, paclitaxel or alectinib (Po0.01; Figure 2a -c). These data suggest that alectinib can enhance the efficacy of conventional substrate chemotherapeutical agents in ABCB1-overexpressing cell xenografts in vivo. Importantly, at the tested doses, no mortality and a significant decrease in body weight were associated with the combination treatment (Figure 2d ), suggesting that the combination regimen did not cause increased toxicity.
Alectinib increased the intracellular accumulation of DOX and Rho 123 in ABCB1-and ABCG2-overexpressing cells Alectinib significantly enhanced the sensitivity of MDR cancer cells to conventional substrate chemotherapeutic agents of ABCB1 or ABCG2 in vitro and in vivo. The main cause of ABC transporter-mediated MDR is the decrease in the intracellular accumulation of chemotherapeutic agents by the agents being pumped out of MDR cells. To investigate the potential mechanism, we measured the intracellular accumulation of DOX and Rho 123 in the presence or absence of alectinib in the KBv200 and S1-MI-80 cells by flow cytometric analysis. Our data showed that the intracellular accumulation of DOX and Rho 123 were significantly lower in the resistant cells than that in the parental sensitive cells (Figure 3) . However, the intracellular accumulations of DOX and Rho 123 were significantly increased in the presence of alectinib in KBv200 and S1-MI-80 cells but not in the sensitive KB and S1 cells ( Figure 3) . Moreover, the increased effect produced by alectinib at 1.5 μM was comparable to that by VRP at 10 μM and FTC at 2.5 μM (Figure 3 ). To confirm whether the increase in intracellular accumulation of DOX and Rho 123 was due to a blockage of transporter-mediated efflux, the time course of intracellular retention of Rho 123 was examined. As we expected, the intracellular retention of Rho 123 was remarkably less in KBv200 and S1-MI-80 cells than that in their corresponding parental KB and S1 cells in the absence of alectinib (Figure 4a and b). In addition, the intracellular retention of Rho 123 was much more in the presence of alectinib in KBv200 and S1-MI-80 cells than in the absence of alectinib, while there are no significant changes in the presence or absence of alectinib in KB and S1 cells at the same time point (Figure 4a and b) . Taken together, the increase in intracellular accumulation of chemotherapeutic agents by alectinib in MDR cells is due to the inhibition of efflux substrate function of ABCB1 and ABCG2. 
Reversal of MDR by alectinib K Yang et al
Alectinib interacted with the drug-substrate-binding sites of ABCB1 and ABCG2 to stimulate their ATPase activity As ABC transporters use energy generated from ATP hydrolysis to pump their substrate agents out of MDR cells against a concentration gradient, ATP consumption thus reflects ATPase activity. To explore the mechanism of the inhibition of ABCB1 and ABCG2 function by alectinib, we first evaluated vanadatesensitive ABCB1 or ABCG2 ATPase activity in the presence of a range of concentrations of alectinib. ABCB1 ATPase activity was stimulated by alectinib until it reached a plateau near 55 nmol min − 1 per mg protein, and it remained steady at alectinib concentrations 45 μM. However, a maximum ABCG2 ATPase activity up to 70 nmol min − 1 per mg protein was attained in the presence of 1.25 μM alectinib. At higher concentrations of alectinib, a drop in the stimulated ABCG2 ATPase activity was observed (Figure 4c and d) . It was observed that alectinib stimulated the ATPase activity similar to other substrates by interacting with the drug-substratebinding sites on the transporters.
It has been reported that the substrates or inhibitors of ABCB1 or ABCG2 can compete with [ 125 I]-IAAP for photolabeling of the respective transporters. 41 
Alectinib alters neither the expression levels nor the cell surface localization of ABCB1 and ABCG2 The reversal of ABCB1-and ABCG2-mediated drug resistance by alectinib could be achieved by either antagonizing the function or decreasing the expression levels of the transporters. Therefore, the effect of alectinib on the protein and mRNA expression levels of ABCB1 and ABCG2 was detected by western blot and RT-PCR assays, respectively. Alectinib did not alter the protein level of either transporter, even at concentrations up to 15.0 μM (Figure 5a and b) . The mRNA expression of ABCB1 or ABCG2 was also unchanged (Figure 5c  and d) . In addition, we further performed a flow cytometric assay to determine the effect of alectinib on the cell surface localization of ABCB1 and ABCG2. Alectinib influenced neither the cell surface expression nor the intracellular localization of ABCB1 and ABCG2 (Figure 5e and f) . Thus, these results suggest that the enhancement of chemotherapeutic agents by alectinib is neither associated with the expression levels of protein and mRNA nor the localization of ABCB1 or ABCG2 protein.
Alectinib did not block the phosphorylation of AKT and ERK in the concentration of reversal MDR Some studies have reported that blocking the phosphorylation of AKT or ERK could increase cancer cell sensitivity to chemotherapeutic agents. 43, 44 Alectinib is a potent ALK and c-Met inhibitor that regulates several important downstream signaling molecules such as AKT and ERK. As we did not detect the expression of ALK in KBv200 and S1-MI-80 cells and their parental sensitive cells, we investigated whether 
Alectinib effectively reversed MDR in ex vivo
It has been reported that ABCB1 is expressed in both AML and CML. 45, 46 To investigate whether alectinib could reverse ABCB1-mediated MDR in ex vivo, bone marrow samples were collected from resistant patients with AML or CML. Four of the eleven patient samples exhibited high expression of ABCB1 (Figure 7a ). We then examined the effect of alectinib on the intracellular accumulation of Rho 123 in these ABCB1-overexpressing primary leukemia blast samples using flow cytometric analysis. As shown in Figure 7b and c, alectinib significantly increased the intracellular accumulation of Rho 123. In addition, we used MTT assays to assess the sensitization effect of alectinib in these samples. The result revealed that 1.5 μM alectinib significantly increased the sensitivity of all four samples to DOX, which exhibited similar efficiency to 10 μM VRP (Figure 7d ). These results suggest that alectinib is able to sensitize ABCB1-overexpressing primary leukemia cells to conventional anticancer drugs, and thus, it might be useful in combination regimens to combat ABCB1-mediated MDR in the clinic. The schematic model illustrating the reversal of MDR by alectinib was showed in Figure 8 .
DISCUSSION
Although chemotherapy offers clinical benefits in many cancers, its impact on chemo-resistant patients is still limited, likely due to MDR, which prevents a full beneficial response. The two most variously studied MDR transporters, ABCB1 and ABCG2, are known to be highly expressed in cancer cells with MDR phenotypes and actively efflux drugs. It is therefore logical to speculate that developing and identifying modulators that regulate these transporters or block their function may provide an effective strategy to circumvent MDR.
Currently, two approved ALK inhibitors, crizotinib and ceritinib, have been reported to have potent reversing activity in ABCB1-or ABCG2-overexpressing MDR cells in vitro and in vivo, 47, 48 suggesting that ALK inhibitors may have an important interaction with ABC transporters, such as ABCB1 and ABCG2. Here we showed for the first time that alectinib significantly potentiated the efficacy of substrate chemotherapeutic agents in ABCB1-or ABCG2-overexpressing cells under the more than 90% cell survival concentration of alectinib, while it did have any effect on the chemotherapeutic sensitivity of their parental cells. More importantly, alectinib did not enhance the cytotoxicity of cisplatin (non-substrate of ABCB1 and ABCG2) in ABCB1-or ABCG2-overexpressing cells. Alectinib also remarkably potentiated the anticancer efficacy of paclitaxel in the ABCB1-overexpressing KBv200 cell xenograft model. Thus, alectinib specifically enhanced the efficacy of chemotherapeutic agents in ABCB1-or ABCG2-overexpressing cells in vitro and in vivo.
Consistent with the enhancement of chemotherapeutic agents by alectinib in vitro and in vivo, alectinib was found to increase the intracellular accumulation of DOX and Rho 123 in ABCB1-or ABCG2-overexpressing cells. This effect was achieved by inhibiting the efflux function of the ABCB1 or ABCG2 transporter. The stimulation of ATPase activity of ABCB1 and ABCG2 by alectinib at low concentrations suggests that alectinib may be similar to their substrates. In other words, alectinib seems to be a competitive inhibitor of these transporters. The interactions of alectinib to ABCB1 and ABCG2 were further confirmed by its competition with the [ 125 I]-IAAP photoaffinity labeling of the transporters.
These results are consistent with our earlier findings with other TKIs. 18, 20 It was reported that the blockage of AKT or ERK phosphorylation could increase cancer cell sensitivity to anticancer drugs such as cisplatin. 43, 44 Some TKIs such as gefitinib and afatinib can also downregulate ABCG2 expression. 18, 37 Because alectinib is an ALK and c-Met TKI, it could inhibit phosphorylation of signals downstream AKT and ERK in ALK-or c-Met-positive NSCLC cells. 26 However, alectinib altered neither the mRNA and protein expression levels and localization of ABCB1/ABCG2 nor the phosphorylation levels of c-Met, AKT and ERK at the reversal MDR concentrations. These suggest that the reversal of MDR by alectinib results from the inhibition of ABCB1/ABCG2 transport function but does not involve in the alteration of their expression levels of mRNA and protein or membrane localization.
Treatment failure in AML is frequently due to resistance to chemotherapy through different mechanisms, in which drug efflux via ATP-binding cassette (ABC) proteins, specifically ABCB1, is one of the most recognized. It has been reported that 23 of 63 (28.6%) of newly treated patients and 11 of 22 (59.1%) of relapsed/refractory patients exhibited high ABCB1 expression. In primary leukemia cells ex vivo, 4 of 11 (36.3%) of leukemic blast samples overexpressed ABCB1. Importantly, alectinib significantly increased the accumulation of Rho 123 and enhanced the cytotoxicity of DOX in these ABCB1-overexpressing primary leukemic blast cells. Consequently, these results suggest that alectinib can reverse ABCB1-mediated MDR ex vivo, which encourages combinational therapies of alectinib and conventional chemotherapeutic drugs in cancer patients with ABCB1-mediated MDR and deserves further study in the clinic.
In conclusion, we provide the first in vitro, in vivo and ex vivo evidence that alectinib significantly enhances the efficacy of chemotherapeutic agents in ABCB1-and ABCG2-overexpressing cells. The reversal of MDR by alectinib was mediated by inhibition of ABCB1/ABCG2 transport function, resulting in an increase in the intracellular accumulation of substrate chemotherapeutic drugs. These positive finding suggest that combinational therapies of alectinib with conventional ABCB1 or ABCG2 substrate chemotherapeutic drugs may benefit patients with ABCB1-or ABCG2-mediated MDR.
